Next, we calculated the half maximal inhibitory concentration (IC50) of osteosarcoma cells (Figure 7B and Supplementary Figure 4B), results from which maintained the conclusion that lnc-RAB11B-AS1 enhanced the sensitivity of osteosarcoma cells to cisplatin. Here, RAB11B is linked to osteosarcoma.